FGI-104

FGI-104
[[File:|frameless|220px|alt=|]]
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

FGI-104 is an investigational antiviral compound that has shown potential in the treatment of various viral infections. It is primarily studied for its efficacy against filoviruses, such as Ebola virus and Marburg virus.

Mechanism of Action

FGI-104 functions by inhibiting the entry of viruses into host cells. It targets the viral glycoproteins that are essential for the fusion of the viral envelope with the host cell membrane. By blocking this critical step, FGI-104 prevents the virus from replicating within the host.

Pharmacokinetics

The pharmacokinetic profile of FGI-104 is still under investigation. Preliminary studies suggest that it has a moderate half-life, allowing for potential once-daily dosing. The compound is believed to be metabolized in the liver, with renal excretion of its metabolites.

Clinical Trials

FGI-104 is currently undergoing clinical trials to evaluate its safety and efficacy. Early-phase trials have demonstrated promising results in terms of reducing viral load and improving survival rates in animal models. Human trials are in the early stages, focusing on safety and dosage optimization.

Potential Applications

FGI-104 is being explored for use in outbreaks of Ebola virus disease and Marburg virus disease. Its broad-spectrum antiviral activity also suggests potential applications against other RNA viruses.

Safety and Side Effects

As with any investigational drug, the safety profile of FGI-104 is not fully established. Common side effects observed in early trials include mild gastrointestinal disturbances and transient liver enzyme elevations. Long-term safety data are not yet available.

Research and Development

FGI-104 is being developed by a consortium of researchers and pharmaceutical companies. The development process involves collaboration with governmental and non-governmental organizations to expedite the availability of the drug in response to viral outbreaks.

See Also

• Antiviral drug
• Ebola virus
• Marburg virus

Drugs for HIV Infection, in the Subclass Antiretroviral Agents

• Fusion Inhibitors (HIV)
  • Enfuvirtide, Maraviroc

• Integrase Inhibitors (HIV)
  • Dolutegravir, Elvitegravir, Raltegravir

• Monoclonal Antibodies
  • Ibalizumab

• Nonnucleoside Reverse Transcriptase Inhibitors (HIV)
  • Delavirdine, Efavirenz, Etravirine, Nevirapine, Rilpivirine

• Nucleoside Analogues (HIV)
  • Abacavir, Didanosine, Emtricitabine, Lamivudine, Stavudine, Tenofovir, Zidovudine

• Protease Inhibitors (HIV)
  • Amprenavir, Atazanavir, Darunavir, Fosamprenavir, Indinavir, Lopinavir, Nelfinavir, Ritonavir, Saquinavir, Tipranavir

Drugs for Hepatitis B

• Alpha Interferon, Adefovir, Emtricitabine, Entecavir, Lamivudine, Telbivudine, Tenofovir

Drugs for Hepatitis C

• Interferon Based Therapies
  • Alpha Interferon and Peginterferon, Ribavirin

HCV NS5A Inhibitors

• Daclatasvir, Elbasvir, Ledipasvir, Ombitasvir, Pibrentasvir, Velpatasvir

HCV NS5B Inhibitors (Polymerase inhibitors)

• Dasabuvir, Sofosbuvir

HCV Protease Inhibitors

• Asunaprevir, Boceprevir, Glecaprevir, Grazoprevir, Paritaprevir, Simeprevir, Telaprevir, Voxilaprevir

Combination Therapies

• Epclusa, Harvoni, Mavyret, Technive, Viekira Pak, Vosevi, Zepatier

Drugs for Herpes Virus

• infections (HSV), CMV, others

Acyclovir, Cidofovir, Famciclovir, Foscarnet, Ganciclovir, Valacyclovir, Valganciclovir

Drugs for Influenza

• Amantadine, Oseltamivir, Peramivir, Rimantadine, Zanamivir

• 
  FGI-104